ABSTRACT
The aim of this study was to estimate the amount of childhood hepatitis B virus transmission in children born in the UK, a very low-prevalence country, that is preventable only by universal hepatitis B immunization of infants. Oral fluid specimens were collected from schoolchildren aged 7-11 years in four inner city multi-ethnic areas and tested for the presence of antibody to hepatitis B core antigen (anti-HBc). Those found positive or indeterminate were followed up with testing on serum to confirm their hepatitis B status. The overall prevalence of anti-HBc in children was low [0.26%, 95% confidence interval (CI) 0.14-0.44]. The estimated average annual incidence of hepatitis B was estimated to be 29.26/100 000 children (95% CI 16.00-49.08). The total incidence that is preventable only by a universal infant immunization programme in the UK was estimated to be between 5.00 and 12.49/100 000. The study demonstrates that the extent of horizontal childhood hepatitis B virus transmission is low in children born in the UK and suggests that schools in the UK are an uncommon setting for the transmission of the virus. Targeted hepatitis B testing and immunization of migrants from intermediate- and high-prevalence countries is likely to be a more effective measure to reduce childhood transmission than a universal infant immunization programme.
Subject(s)
Ethnicity , Hepatitis B/epidemiology , Hepatitis B/transmission , Child , Cross-Sectional Studies , Emigrants and Immigrants , England/epidemiology , Family , Female , Hepatitis B/ethnology , Hepatitis B/prevention & control , Hepatitis B virus/immunology , Humans , Male , Population Surveillance , Surveys and QuestionnairesABSTRACT
In spring 2009 a new strain of influenza A(H1N1) emerged and caused a worldwide pandemic. This study utilized a large collection of respiratory specimens from suspected cases of influenza A(H1N1) in the UK West Midlands during the pandemic in order to investigate which other respiratory viruses were circulating and whether they played any role in the increased hospitalization rates seen during that period. Study specimens were selected from community and hospitalized patients positive and negative for influenza A(H1N1) and tested by PCR for other respiratory viruses. A number of infections diagnosed as influenza during the summer influenza outbreak were found to be due to other virus infections (most commonly rhinovirus). No statistically significant difference was found between the rates of respiratory virus co-infection with H1N1 in patients from community or hospital locations suggesting underlying factors were likely to be more significant than viral co-infections in determining severity of influenza A(H1N1) disease.
Subject(s)
Influenza A Virus, H1N1 Subtype/isolation & purification , Influenza, Human/epidemiology , Influenza, Human/virology , Pandemics , Respiratory Tract Infections/epidemiology , Respiratory Tract Infections/virology , Viruses/isolation & purification , Adolescent , Adult , Child , Child, Preschool , Coinfection , England/epidemiology , Hospitalization , Humans , Influenza A Virus, H1N1 Subtype/classification , Influenza, Human/diagnosis , Middle Aged , Prevalence , Respiratory Tract Infections/diagnosis , Seasons , Viruses/genetics , Young AdultABSTRACT
The purpose of this study was to validate through natural exposure a cut-off level of varicella zoster IgG as protective against infection with varicella zoster virus (VZV). Laboratory testing to determine VZV immune status of pregnant women exposed to varicella is recommended. Quantitative assays are now available which are sensitive and specific. More than 200 consecutive requests for screening in pregnant patients with recent varicella contacts were followed-up by questionnaire. DiaSorin LIAISON and VZV time resolved fluorescence immuno assay (VZV TRFIA) were used to measure VZV antibody level. One hundred fifty out of 209 (72%) questionnaires were returned; 14 patients developed varicella, 129 did not and seven were not known. Patients who had been given VZIG and developed varicella on follow-up had a mean antibody level before VZIG of 28 mIU/ml and 62 mIU/ml, by LIAISON and TRFIA, respectively. The mean IgG level of those that did not develop varicella was 885 and 866 mIU/ml by LIAISON and TRFIA, respectively. Those with levels <100 mIU/ml were more likely to develop chicken pox than those with levels >100 mIU/ml (relative risk of 10.4 for LIAISON and 8.8 for TRFIA). On the basis of the relatively small numbers in this study, quantitative assays, using a 100mIU/ml cut-off, can differentiate between those who are susceptible and those who are protected against exposure, however follow-up studies should include sampling for VZV DNA and IgM.
Subject(s)
Antibodies, Viral/blood , Chickenpox/diagnosis , Chickenpox/pathology , Herpesvirus 3, Human/isolation & purification , Pregnancy Complications, Infectious/diagnosis , Pregnancy Complications, Infectious/pathology , Chickenpox/immunology , Chickenpox/virology , Female , Follow-Up Studies , Herpesvirus 3, Human/immunology , Humans , Immunoassay/methods , Immunoglobulin G/blood , Immunoglobulin M/blood , Immunoglobulins, Intravenous/administration & dosage , Immunologic Factors/administration & dosage , Pregnancy , Pregnancy Complications, Infectious/immunology , Pregnancy Complications, Infectious/virology , Surveys and QuestionnairesABSTRACT
BACKGROUND: Determination of Varicella Zoster virus (VZV) immune status in pregnant women without history of chickenpox is important in identifying those who genuinely need VZV immune globulin prophylaxis following significant exposure to chickenpox or shingles. Immune status testing requires highly sensitive and specific immunoassays for timely and accurate results. OBJECTIVES: To compare the performance of DiaSorin LIAISON and Biomerieux VIDAS VZV-IgG assays with reference to a VZV-IgG time-resolved fluorescence immunoassay (TRFIA). STUDY DESIGN: A panel of sera collected from 65 pregnant contacts of VZV and 62 individuals tested for VZV immunity was tested in all three assays. Dose-response curves were generated using International Standards W1044 and 90/690. RESULTS: Sensitivity and specificity of VIDAS compared to VZV-TRFIA was 54.5% and 97.9% respectively and for LIAISON compared to VZV-TRFIA was 67% and 100% respectively. Both assays correlated well with TRFIA with R2 correlation coefficients of 0.79 and 0.76 respectively. Dose-response curves showed both Standards behaved in a similar manner in each assay. For VIDAS, the test cut-off value of 0.9 correlated with 275-280mIU/ml and for LIAISON a cut-off value of 150mIU/ml correlated with 208-219mIU/ml. CONCLUSIONS: By dose-response data and in comparison with TRFIA, LIAISON is more sensitive and specific than VIDAS.
Subject(s)
Antibodies, Viral/blood , Chickenpox/prevention & control , Herpes Zoster/prevention & control , Herpesvirus 3, Human/immunology , Immunoglobulin G/blood , Chickenpox/diagnosis , Female , Fluorescence , Herpes Zoster/diagnosis , Herpesvirus 3, Human/isolation & purification , Humans , Immunoassay/methods , Pregnancy , Sensitivity and SpecificityABSTRACT
BACKGROUND: Hepatitis B vaccine and hepatitis B immunoglobulin are considered for newborn infants of HBsAg-positive mothers to prevent hepatitis B infection. OBJECTIVES: To assess the beneficial and harmful effects of hepatitis B vaccines and hepatitis B immunoglobulin in newborn infants of HBsAg-positive mothers. SEARCH STRATEGY: Trials were identified through The Cochrane Neonatal Group Controlled Trials Register, The Cochrane Hepato-Biliary Group Controlled Trials Register, The Cochrane Central Register of Controlled Trials in The Cochrane Library, MEDLINE, and EMBASE (until February 2004), authors of trials, and pharmaceutical companies. SELECTION CRITERIA: Randomised clinical trials comparing: plasma-derived vaccine (PDV) or recombinant vaccine (RV) versus no intervention, placebo, or other active vaccines; hepatitis B immunoglobulin versus no intervention, placebo, or other control immunoglobulin; as well as PDV or RV plus hepatitis B immunoglobulin versus no intervention, placebo, or other control vaccines or immunoglobulin. DATA COLLECTION AND ANALYSIS: Outcomes are assessed at maximal follow-up. The primary outcome measure was hepatitis B occurrence, based on a blood specimen positive for HBsAg, HBeAg, or antibody to hepatitis B core antigen (anti-HBc). Binary outcomes are reported as relative risks (RR) with 95% confidence interval (CI). Subgroup analyses were performed with regard to methodological quality of the trial, mother's HBe-Ag status, and time of immunisation after birth. MAIN RESULTS: We identified 29 randomised clinical trials, five of which were considered high quality. Only three trials reported inclusion of hepatitis B e-antigen negative mothers. Compared with placebo/no intervention, vaccine reduced hepatitis B occurrence (RR 0.28, 95% confidence interval (CI) 0.20 to 0.40, 4 trials). No significant differences of hepatitis B occurrence were found comparing recombinant vaccine (RV) versus plasma-derived vaccine (PDV) (RR 1.00, 95% CI 0.71 to 1.42, 4 trials) and high-dose versus low-dose vaccine (PDV: RR 0.97, 95% CI 0.55 to 1.68, 3 trials; RV: RR 0.78, 95% CI 0.31 to 1.94, 1 trial). Compared with placebo/no intervention, hepatitis B immunoglobulin or the combination of vaccine plus hepatitis B immunoglobulin reduced hepatitis B occurrence (hepatitis B immunoglobulin: RR 0.50, 95% CI 0.41 to 0.60, 1 trial; PDV plus hepatitis B immunoglobulin: RR 0.08, 95% CI 0.03 to 0.17, 3 trials). Compared with vaccine, vaccine plus hepatitis B immunoglobulin reduced hepatitis B occurrence (RR 0.54, 95% CI 0.41 to 0.73, 10 trials). Hepatitis B vaccine and hepatitis B immunoglobulin seem safe, but few trials reported on adverse events. AUTHORS' CONCLUSIONS: Vaccine, hepatitis B immunoglobulin, and vaccine plus hepatitis B immunoglobulin prevent hepatitis B occurrence in newborn infants of HBsAg positive mothers.
Subject(s)
Hepatitis B Antibodies/therapeutic use , Hepatitis B Vaccines/therapeutic use , Hepatitis B e Antigens/blood , Hepatitis B/prevention & control , Female , Hepatitis B/immunology , Humans , Infant, Newborn , Randomized Controlled Trials as TopicABSTRACT
BACKGROUND: Laboratory-based study funded by the Research and Development Division of the Department of Health to inform the decision making on guidelines for the conduct of exposure prone procedures (EPPs) by health care workers who are hepatitis B carriers. OBJECTIVES: Define the quantity and nature of hepatitis B virus (HBV) DNA in hepatitis carriers whose serum does not contain hepatitis B e antigen (HBeAg) and in surgeons previously cleared to conduct EPPs who have transmitted HBV to their patients. STUDY DESIGN: Cross-sectional survey using HBV DNA quantification, genotyping and sequencing comparing transmitting surgeons and asymptomatic carriers. RESULTS: HBV DNA could be detected and quantified in 64.5% (136 of 211) of carriers whose serum did not contain HBeAg with a median level 3.6 log(10) copies/ml (range of 5.7 log(10) copies). Pre-core mutation appeared not to affect the HBV DNA level, however, all surgeons carried codon 28 variants and transmitted these variants to their patients. The lowest HBV DNA level in a transmitting surgeon was 4 x 10(4) copies/ml. CONCLUSIONS: Pre-core mutations are common in carriers whose serum does not contain HBeAg and do not specifically identify carriers whose HBV DNA levels are high. It was possible to define a level of virus above which transmission of hepatitis B during conduct of EPPs could not be excluded.
Subject(s)
DNA, Viral/blood , General Surgery , Health Personnel , Hepatitis B virus/isolation & purification , Hepatitis B/transmission , Infectious Disease Transmission, Professional-to-Patient , Carrier State/transmission , Carrier State/virology , Hepatitis B/virology , Hepatitis B e Antigens/blood , Hepatitis B virus/classification , Hepatitis B virus/genetics , HumansABSTRACT
The HAVAB radioimmunoassay for the detection of antibody to hepatitis A is assessed. Its modification to detect virus in faecal samples is described and in this it was found to be more sensitive and specific than electron microscopy.
Subject(s)
Antibodies, Viral/analysis , Antigens, Viral/analysis , Hepatovirus/immunology , Animals , Antibody Specificity , Feces/analysis , Feces/microbiology , Hepatitis A/diagnosis , Humans , Microscopy, Electron , Pan troglodytes , RadioimmunoassayABSTRACT
AIMS: To validate the sensitivity of universal antenatal screening for hepatitis B surface antigen (HBsAg) by testing pools of 10 sera, and to review 10 years' experience using this method. METHODS: 66,945 antenatal patients were tested between 1986 and 1996 using the pooled method. All sera from 1996 (n = 6050) were retrieved and retrospectively tested individually. An in vitro determination of the effect of pooling on sensitivity was performed by checkerboard neutralisation assay. RESULTS: 26 HBsAg positive women were detected by universal screening over 10 years; 12 had non-European surnames and five had known risk factors for hepatitis B infection. High titre anti-HBs sera in the pool reduced the sensitivity of the HBsAg assay, though the effect was only significant at low levels of HBsAg carriage. CONCLUSIONS: The prevalence of hepatitis B is extremely low in the antenatal population served by Plymouth PHL. Pooling is unlikely to reduce sensitivity enough to lead to significant preventable vertical transmission, and is a cost-effective and valid strategy in areas of low seroprevalence.
Subject(s)
Blood Specimen Collection/methods , Hepatitis B/prevention & control , Mass Screening/methods , Pregnancy Complications, Infectious/prevention & control , Prenatal Care/methods , Carrier State/prevention & control , England , Female , Hepatitis B Surface Antigens/blood , Humans , Infectious Disease Transmission, Vertical/prevention & control , Pregnancy , Retrospective Studies , Sensitivity and SpecificityABSTRACT
A field trial of an enzyme-linked immunosorbent assay (ELISA) for the detection of the hepatitis Be markers is reported. It is simple to perform, is designed to be read by eye and does not require any expensive apparatus. When compared with a commercially available RIA kit for the detection of the same markers, ELISA was shown to be as sensitive as RIA for the detection of anti-HBe but slightly less sensitive for the detection of HBeAg. However if all specimens negative for both HBeAg and anti-HBe by ELISA are considered to be potentially infectious, the ELISA should prove to be as useful as RIA for determining the "e" status of HBsAg-positive patients and, therefore, provide a reliable indication of the risk of secondary spread of hepatitis B infection to contacts by needle stick accident, close personal contact or perinatal transmission.
Subject(s)
Antibodies, Viral/analysis , Hepatitis B Antibodies/analysis , Hepatitis B Antigens/analysis , Hepatitis B e Antigens/analysis , Enzyme-Linked Immunosorbent Assay , Hepatitis B e Antigens/immunology , RadioimmunoassayABSTRACT
A range of solid phase immunoassays have been developed using enhanced chemiluminescence to provide a signal which can be measured in a qualitative or quantitative manner. The "Amerlite" anti-HBs assay has been used routinely to test more than 3000 post-vaccine anti-HBs levels. The results show that 5% of vaccinees are non-responders, but that more than 30% produce antibody levels greater than 1000 mIU/ml.
Subject(s)
Hepatitis B Antibodies/blood , Hepatitis B/prevention & control , Immunoassay/methods , Vaccination , Adolescent , Adult , Aged , Antibody Formation , Biomarkers , Female , Humans , Luminescent Measurements , Male , Middle Aged , Reagent Kits, DiagnosticABSTRACT
Forty-one faecal samples from infectious-hepatitis patients and their contacts were investigated for the presence of hepatitis-A-associated viral particles. Of these, 16 gave a positive result by immune electronmicroscopy or caesium-chloride density-gradient centrifugation. The latter method proved invaluable in detecting small numbers of virus particles. The particles found had buoyant density of 1-34-1-35 and a size range of 21-28 nm. Epidemiological evidence suggested that they might be the causative agent of hepatitis A.
Subject(s)
Feces/microbiology , Hepatitis A/microbiology , Hepatovirus , Antigens, Viral/analysis , Centrifugation, Density Gradient , Coliphages/ultrastructure , Cross Reactions , Enterovirus B, Human/ultrastructure , Female , Hepatovirus/immunology , Hepatovirus/isolation & purification , Hepatovirus/ultrastructure , Humans , Male , Microscopy, ElectronABSTRACT
A colourimetric assay for the analysis of point mutations in PCR amplified DNA fragments from hepatitis B virus (HBV) is described. The method was applied for analysis of the single point mutation in codon 28 of the precore gene of HBV, which inhibits expression of HBe antigen. The assay, which uses a microtitre plate formate, incorporates fluorescein-labelled dideoxynucleotides as opposed to radioactively-labelled deoxynucleotides used in methods described previously. Synthetic control wild type and mutant oligonucleotides were tested to optimise the reaction conditions. The assay was thus shown to yield both qualitative and quantitative data on the relative proportions of wild type and mutant sequences within a given sample. Amplicons from clinical specimens of known sequence were analysed to validate the assay. Sixteen chronic carriers of HBV were tested using the codon 28 point mutation assay, and the results were confirmed by direct sequencing. The method described is suitable for applications where point mutations are of interest.
Subject(s)
Hepatitis B virus/chemistry , Hepatitis B virus/genetics , Point Mutation , Colorimetry/methods , DNA Mutational Analysis , Hepatitis B/genetics , Hepatitis B/virology , Humans , Polymerase Chain Reaction , Sensitivity and SpecificityABSTRACT
A modification of the Blood Products Laboratory radioimmunoassay for hepatitis B surface antigen which allows simultaneous assay of both hepatitis B surface antigen and antibody is described. The sensitivity of the method has been assessed and its performance as a screening test in over 2,500 routine samples has been evaluated.
Subject(s)
Hepatitis B Antibodies/analysis , Hepatitis B Surface Antigens/analysis , Evaluation Studies as Topic , Hemagglutination Inhibition Tests , Hemagglutination Tests , Humans , Radioimmunoassay , Reagent Kits, DiagnosticABSTRACT
Until recently, carriers of hepatitis B virus (HBV) were allowed to undertake exposure prone procedures providing their serum did not contain HBeAg. However, the recent description of hepatitis B transmission events occurring from HBV-infected health care workers who conduct exposure prone procedures demonstrated that the then current Department of Health guidelines needed to be revised. As part of a series of studies carried out to determine if viral load measurements are a more secure means of assessing the conduct of exposure prone procedures, the suitability of commercially available assays for HBV DNA detection and quantification were investigated. This study describes a comparative analysis on the performances of three assays each based on a different methodology. The assays included the QUANTIPLEX HBV DNA Assay (bDNA), (Chiron Diagnostics Ltd.), the AMPLICOR HBV Monitor Test, (Roche Diagnostics Systems) and the Digene Hybrid Capture System HBV DNA Assay (Digene Corporation). Calibration curves from experiments using the Eurohep ad and ay HBV DNA standard controls indicated a close correlation between the three assays over the dynamic ranges claimed by the manufacturers, although the Quantiplex assay did appear to be over-reporting. This became more apparent when testing patients undergoing anti-viral therapy where the Quantiplex assay consistently over-reported by 0.5 log(10) when compared with the Amplicor assay. The results of this study indicate that based on its dynamic range, the Amplicor HBV Monitor test is the most appropriate assay for the routine investigation of anti-HBe carriers, which will have lower levels of HBV DNA. The investigation also highlights the need for using accepted standard HBV DNA control sera. This will be essential when using an assay to establish whether health care workers who are hepatitis B carriers can be allowed to perform exposure prone procedures under the new guidelines of the UK Department of Health.
Subject(s)
DNA, Viral/blood , Health Personnel , Hepatitis B/virology , Polymerase Chain Reaction/methods , Reagent Kits, Diagnostic , Viral Load , Calibration , Hepatitis B/blood , Hepatitis B virus/genetics , HumansABSTRACT
OBJECTIVES: To establish natural seroconversion rates and incidence of hepatic pathology in perinatally infected hepatitis B carriers. METHODS: Seventy three perinatally infected hepatitis B carriers identified through maternal screening were evaluated. Fifty three were born to parents from the Indian subcontinent, nine were Oriental, six were Afro-Caribbean, and five were white. Median follow up was 10.24 (range 2.02-20.16) years. RESULTS: Only three of the children followed up had cleared hepatitis B surface antigen during this period, and 30% of the children had seroconverted to anti-HBe. Seroconversions to anti-HBe were observed in Asian (18/50) and white (4/5) children, but not in Oriental or Afro-Caribbean children. More girls (40%) than boys (23%) had seroconverted, but the difference was not significant. All children were asymptomatic with normal physical examination, growth, and development. Almost half (48%) of the hepatitis B e antigen (HBeAg) positive children had normal hepatic transaminases and liver function. Thirty five liver biopsies were performed in children with active virus replication (HBeAg or hepatitis B virus DNA positive) who were being considered for antiviral treatment as part of a clinical trial and were scored using the Ishak method. Two thirds (62%) of the children had mild hepatitis, 60% had mild fibrosis, and 18% had moderate to severe fibrosis. There was a weak correlation between histological evidence of hepatitis and hepatic transaminase activity, implying that biochemical monitoring of hepatic disease activity may be ineffective. CONCLUSIONS: These asymptomatic hepatitis B virus carrier children remain infectious in the medium to long term with notable liver pathology. They should receive antiviral treatment to reduce infectivity and to prevent further progression of liver disease. Hepatic transaminases alone are not a reliable marker of liver pathology, and liver histology is essential before consideration for antiviral treatment.